Neuraxis Inc. (NRXS)
AMEX AMEX Primary Summary
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs and commercialization investments weigh on profitability.
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
Neuraxis Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JRS James RG Skjong Ulland Investment Advisors LLC | 1,000 | $2,420 | $6,870 | $4,450 | 183.88% |
 Irene Chou Panoramic Capital LLC | 190,000 | $934,100 | $1.31M | $378,800 | 40.55% |
Neuraxis Inc. (NRXS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Neuraxis Inc. ever had a stock split?
Neuraxis Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Carrico CEO | AMEX Exchange | 64134X201 CUSIP |
| US Country | 24 Employees | - Last Dividend | - Last Split | 9 Aug 2023 IPO Date |
Overview
NeurAxis, Inc. is a pioneering medical technology enterprise focused on the innovation of neuromodulation therapies. These therapies are devised to alleviate chronic and debilitating conditions affecting both children and adults throughout the United States. Initially known as Innovative Health Solutions, Inc., the company underwent a name change to NeurAxis, Inc. in March 2022. Founded in 2011 and headquartered in Carmel, Indiana, NeurAxis, Inc. is at the forefront of offering groundbreaking solutions, significantly enhancing patient care. The company primarily caters to healthcare providers, including hospitals and clinics, distributing its technological advancements widely across the healthcare sector.
Products and Services
Listed below are the products and services offered by NeurAxis, Inc.:
- IB-Stim:
This is a cutting-edge percutaneous electrical nerve field stimulation system. It's specifically designed for use in younger patients, ranging from 11 to 18 years of age, who suffer from functional abdominal pain associated with irritable bowel syndrome (IBS). The system operates by delivering targeted electrical nerve field stimulation, providing a non-pharmacological treatment option that aims to significantly reduce the symptoms of IBS in this age group. By focusing on such a niche, NeurAxis, Inc. contributes to fulfilling a critical gap in pediatric healthcare solutions.
